Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon

Journal of Virology

Volumn 83, Issue 13, 2009, Pages 6383-6390

  Dahari, Harel ^a   Sainz Jr , Bruno ^a   Perelson, Alan S ^b   Uprichard, Susan L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; KINETICS; MATHEMATICAL MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; RNA DEGRADATION; RNA STABILITY; VIRUS GENOME; VIRUS INHIBITION; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; THEORETICAL MODEL; TIME; VIRUS REPLICATION;

HEPATITIS C VIRUS;

CELL LINE; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; KINETICS; MODELS, THEORETICAL; RNA, VIRAL; TIME FACTORS; VIRUS REPLICATION;

EID: 67449089969     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02612-08     Document Type: Article

References (28)

1. Bartenschlager, R. 2005. The hepatitis C virus replicon system: from basic research to clinical application. J. Hepatol. 43:210-216. (Pubitemid 40956872)
2. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
3. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946-952. (Pubitemid 41191670)
4. Dahari, H., J. E. Layden-Almer, A. S. Perelson, and T. J. Layden. 2008. Hepatitis C viral kinetics in special populations. Curr. Hepat. Rep. 7:97-105.
5. Dahari, H., and A. S. Perelson. 2007. Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 46:2048-2049.
6. Dahari, H., R. M. Ribeiro, C. M. Rice, and A. S. Perelson. 2007. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 81:750-760. (Pubitemid 46067901)
7. Dahari, H., E. Shudo, R. M. Ribeiro, and A. S. Perelson. 2008. Mathematical modeling of HCV RNA kinetics. In H. Tang (ed.), Hepatitis C protocols, 2nd ed. Humana Press, Totowa, NJ.
8. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
9. Inoue, K., T. Umehara, U. T. Ruegg, F. Yasui, T. Watanabe, H. Yasuda, J. M. Dumont, P. Scalfaro, M. Yoshiba, and M. Kohara. 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:921-928. (Pubitemid 46631561)
10. Kapadia, S. B., A. Brideau-Andersen, and F. V. Chisari. 2003. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA 100:2014-2018.
11. Lin, K., A. D. Kwong, and C. Lin. 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 48:4784-4792.
12. Lin, K., R. B. Perni, A. D. Kwong, and C. Lin. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50:1813-1822.
13. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. (Pubitemid 32913521)
14. Nelson, H. B., and H. Tang. 2006. Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J. Virol. 80:1181-1190. (Pubitemid 43134075)
15. Neumann, A. U., N. P. Lam, H. Dahari, M. Davidian, T. E. Wiley, B. P. Mika, A. S. Perelson, and T. J. Layden. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182:28-35.
16. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107. (Pubitemid 28471138)
17. National Institutes of Health. 2002. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology 36(Suppl. 1):S3-S20.
18. Nguyen, T. T., A. Sedghi-Vaziri, L. B. Wilkes, T. Mondala, P. J. Pockros, K. L. Lindsay, and J. G. McHutchison. 1996. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J. Viral Hepat. 3:75-78. (Pubitemid 126734187)
19. Pause, A., G. Kukolj, M. Bailey, M. Brault, F. Do, T. Halmos, L. Lagace, R. Maurice, M. Marquis, G. McKercher, C. Pellerin, L. Pilote, D. Thibeault, and D. Lamarre. 2003. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278:20374-20380.
20. Pawlotsky, J. M., H. Dahari, A. U. Neumann, C. Hezode, G. Germanidis, I. Lonjon, L. Castera, and D. Dhumeaux. 2004. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703-714. (Pubitemid 38298318)
21. Pedersen, I. M., G. Cheng, S. Wieland, S. Volinia, C. M. Croce, F. V. Chisari, and M. David. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922. (Pubitemid 47598616)
22. Perelson, A. S., E. Herrmann, F. Micol, and S. Zeuzem. 2005. New kinetic models for the hepatitis C virus. Hepatology 42:749-754. (Pubitemid 41401110)
23. Pietschmann, T., V. Lohmann, G. Rutter, K. Kurpanek, and R. Bartenschlager. 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:1252-1264. (Pubitemid 32094684)
24. Pilli, M., A. Zerbini, A. Penna, A. Orlandini, E. Lukasiewicz, J. M. Pawlotsky, S. Zeuzem, S. W. Schalm, M. von Wagner, G. Germanidis, Y. Lurie, J. I. Esteban, B. L. Haagmans, C. Hezode, M. Lagging, F. Negro, Y. Homburger, A. U. Neumann, C. Ferrari, and G. Missale. 2007. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133:1132-1143. (Pubitemid 47494444)
25. Simmen, K., O. Lenz, T. Lin, P. Fanning, H. Raoisson, H. de kock, G. Klooster, A. Rosenquist, M. Edlund, M. Nilsson, L. Vrang, and B. Samuelsson. 2007. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Hepatology 46:1390.
26. Taylor, D. R., M. Puig, M. E. Darnell, K. Mihalik, and S. M. Feinstone. 2005. New antiviral pathway that mediates hepatitis C virus replicon Interferon sensitivity through ADAR1. J. Virol. 79:6291-6298. (Pubitemid 40617233)
27. Windisch, M. P., M. Frese, A. Kaul, M. Trippler, V. Lohmann, and R. Bartenschlager. 2005. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 79:13778-13793. (Pubitemid 41508189)
28. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294-9299.